



JUN 22 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/550,968	PATENT DEPARTMENT Mark E. Duggan	21298
JUN 08 2006		INTERNATIONAL APPLICATION NO.
		PCT/US04/08627
210 MERCK AND CO., INC P O BOX 2000 RAHWAY, NJ 07065-0907	J. ERIC THIES	I.A. FILING DATE PRIORITY DATE
		03/22/2004 03/26/2003

DOCKETED

JUN 07 2006

100% SIGNED

Date Mailed: 06/02/2006

CONFIRMATION NO. 4063

371 FORMALITIES LETTER



\*OC000000019069431\*

NMP  
Sequence listing  
due 8/2/06

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice MUST be returned with the response.*

BARBARA A CAMPBELL

---

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/550,968	PCT/US04/08627	21298

---

FORM PCT/DO/EO/922 (371 Formalities Notice)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mark E. Duggan et al

Serial No. : 10/550,968 Case No.: 21298P

Filed : September 26, 2005

For : BENZAMIDE MODULATORS OF METABOTROPIC  
GLUTAMATE RECEPTORS

Commissioner for Patents  
Alexandria, Virginia 22313-1450

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS**  
**FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE**  
**AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures, mailed June 2, 2006 (a copy of which is attached hereto), Applicants note that this application does not disclose any nucleotide and/or amino acid sequences such that 37 CFR 1.827 does not apply. Submission of a Sequence Listing is not appropriate. Any fee deficiencies may be charged to Merck Deposit Account number 13-2755.

Respectfully submitted,

By   
\_\_\_\_\_  
J/Eric Thies  
Reg. No. 35,382  
Attorney for Applicants

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.  
By   
\_\_\_\_\_  
Date 20 June 2006

Date: June 20, 2006

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904